DiaMedica Therapeutics, Inc.
DiaMedica-Logo
Navigate DiaMedica Therapeutics, Inc.
Home
About Us
Company Overview
Leadership Team
Board of Directors
Clinical Advisory Boards
Science
Our Science
Pipeline
Diseases We Target
Overview
IgA Nephropathy
African Americans - Hypertensive with CKD
Acute Ischemic Stroke
Investors & Media
Investors Home
Press Releases
Events & Presentations
Nasdaq Stock Information
Analyst Coverage
Financial Reports
Governance
Investor Resources
Careers
Contact
Home
News
News
All News
By Year:
2020
2019
2018
2017
2016
Nov 28, 2016
DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders
Oct 12, 2016
DiaMedica Establishes Neurological Scientific Advisory Board With Several Distinguished Experts
Oct 5, 2016
DiaMedica Announces First Patient Enrolled in Bridging Clinical Trial for DM199
Sep 26, 2016
DiaMedica to Present at the 16th Annual Biotech in Europe Forum for Global Partnering and Investment Conference
Sep 12, 2016
DiaMedica Announces Regulatory Clearance to Initiate Bridging Clinical Trial for DM199
Sep 8, 2016
DiaMedica Completes Second Tranche of Non-Brokered Private Placement With Hermed Capital
Aug 22, 2016
DiaMedica Completes First Tranche of Non-Brokered Private Placement with Hermed Capital
Jul 17, 2016
DiaMedica Announces Strategic Investment by Hermed Capital Healthcare Fund
Jun 14, 2016
DiaMedica Announces U.S. Composition of Matter Patent for DM199
May 9, 2016
DiaMedica Appoints Dr. Todd Verdoorn as Chief Scientific Officer
« Previous
1
2
3
4
5
6
7
8
9
Next »